Study guide

Asthma and COPD diagnosis and maintenance

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Asthma and COPD diagnosis and maintenance

Key Takeaways Explain This Topic AI

A normal examination between attacks does not exclude asthma.

An inhaled corticosteroid-containing strategy reduces asthma exacerbation risk.

COPD requires persistent airflow obstruction interpreted with the clinical history.

Last updated: October 2026

Diagnostic Evaluation of Obstructive Airway Diseases

Obstructive lung diseases are characterised by limitation of expiratory airflow resulting from airway inflammation, hyperresponsiveness, smooth muscle contraction, and structural parenchymal remodeling. Differentiating asthma from chronic obstructive pulmonary disease (COPD) is essential for selecting appropriate maintenance pharmacotherapy and preventing acute life-threatening decompensations.

Asthma Diagnostic Confirmation

In Australian clinical practice, a diagnosis of asthma requires two distinct elements: a compatible clinical history of episodic respiratory symptoms (wheeze, shortness of breath, chest tightness, and cough) and objective documentation of variable expiratory airflow limitation.

Spirometry with Bronchodilator Reversibility: Spirometry is the definitive first-line diagnostic investigation. Airflow limitation is established by a reduced forced expiratory volume in 1 second to forced vital capacity ratio ( FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 or below the lower limit of normal). Significant bronchodilator reversibility is defined as an increase in FEV 1 \text{FEV}_1 FEV 1 ​ of greater than 12% and greater than 200 mL 200\text{ mL} 200 mL from baseline, measured 10 to 15 minutes after inhaling 400 μ g 400\ \mu\text{g} 400 μ g of salbutamol via a spacer.

Peak Expiratory Flow (PEF) Variability: When spirometry is normal or inconclusive, diurnal PEF variability exceeding 20% over 1 to 2 weeks (calculated from twice-daily recordings) provides objective support for asthma.

Fractional Exhaled Nitric Oxide (FeNO): A FeNO level ≥ 35 ppb \ge 35\text{ ppb} ≥ 35 ppb in non-smoking adults indicates eosinophilic airway inflammation and predicts positive responsiveness to inhaled corticosteroids (ICS), although a normal FeNO does not exclude asthma.

Bronchial Provocation Testing: In patients with normal spirometry and normal reversibility, bronchial challenge testing (using direct agents such as methacholine or indirect agents such as inhaled mannitol) demonstrates bronchial hyperresponsiveness through a 20% drop in FEV 1 \text{FEV}_1 FEV 1 ​ .

COPD Diagnostic Confirmation

COPD is a preventable and treatable disease characterized by persistent respiratory symptoms and non-reversible or partially reversible airflow limitation caused by airway and alveolar abnormalities, predominantly driven by tobacco smoking or occupational exposures in Australia.

Post-Bronchodilator Spirometry: The cornerstone of diagnosis is a post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 . Unlike asthma, significant reversibility to normal values is absent, establishing persistent fixed airflow obstruction.

Spirometric Grading: Airflow limitation severity is staged using post-bronchodilator FEV 1 \text{FEV}_1 FEV 1 ​ percent predicted: Stage 1 (Mild, FEV 1 ≥ 80 % \text{FEV}_1 \ge 80\% FEV 1 ​ ≥ 80% ), Stage 2 (Moderate, 50 % ≤ FEV 1 < 80 % 50\% \le \text{FEV}_1 < 80\% 50% ≤ FEV 1 ​ < 80% ), Stage 3 (Severe, 30 % ≤ FEV 1 < 50 % 30\% \le \text{FEV}_1 < 50\% 30% ≤ FEV 1 ​ < 50% ), and Stage 4 (Very Severe, FEV 1 < 30 % \text{FEV}_1 < 30\% FEV 1 ​ < 30% ).

Typical Onset : Asthma: Childhood or young adulthood, frequently atopic; COPD: Mid-to-late adulthood (>40 years), heavy smoking history

Symptom Pattern : Asthma: Variable, diurnal, episodic, night/early morning waking; COPD: Progressive, chronic dyspnoea on exertion, chronic cough

Spirometry : Asthma: Reversible obstruction ( Δ FEV 1 > 12 % \Delta\text{FEV}_1 > 12\% Δ FEV 1 ​ > 12% and > 200 mL > 200\text{ mL} > 200 mL ); COPD: Fixed obstruction (post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 )

Airway Pathology : Asthma: Eosinophilic and CD4+ T-cell mediated (Th2 pattern); COPD: Neutrophilic and CD8+ T-cell mediated, parenchymal destruction

Primary Treatment : Asthma: Inhaled corticosteroids (ICS) foundational at all stages; COPD: Long-acting bronchodilators (LAMA / LABA) foundational

  • Maintenance Management Frameworks
  • National Asthma Council Australia Stepwise Algorithm

The National Asthma Council (NAC) Australia guidelines have departed from short-acting beta-2 agonist (SABA) monotherapy due to clinical evidence demonstrating that regular or frequent SABA use causes beta-receptor downregulation, increases bronchial hyperresponsiveness, and escalates severe exacerbation and mortality risks.

Anti-Inflammatory Reliever (AIR) Therapy (Steps 1 & 2): For adults and adolescents with mild asthma, as-needed low-dose budesonide-formoterol ( 200 / 6 μ g 200/6\ \mu\text{g} 200/6 μ g ) taken whenever symptoms occur is preferred. Delivering an ICS alongside every bronchodilator dose treats underlying airway inflammation at the earliest sign of symptom worsening.

Maintenance and Reliever Therapy (MART) (Steps 3 & 4): For patients experiencing daytime symptoms more than twice weekly or night waking, a fixed daily maintenance regimen of budesonide-formoterol combined with the same inhaler as an as-needed reliever provides optimal asthma control and halves exacerbation rates compared to fixed-dose regimens using separate SABA relievers.

Add-on Specialist Therapies (Step 5): Patients uncontrolled on medium-to-high dose ICS-LABA warrant add-on long-acting muscarinic antagonists (LAMA, such as tiotropium) and phenotype-directed biologic agents (e.g., omalizumab for severe allergic asthma; mepolizumab, benralizumab, or dupilumab for severe eosinophilic asthma).

COPD Maintenance Pharmacotherapy

COPD maintenance prioritizes symptom reduction, exercise tolerance improvement, and exacerbation prevention.

Pulmonary rehabilitation: Offer to appropriate symptomatic patients, especially after exacerbation. Eligibility depends on symptoms and function rather than a single FEV1 threshold.

Inhaled Bronchodilators: Monotherapy with a LAMA (e.g., tiotropium, glycopyrronium, umeclidinium) or LABA (e.g., indacaterol, formoterol) is initiated for breathlessness. LAMA monotherapy shows slight superiority over LABA monotherapy in reducing exacerbation frequency.

Dual Bronchodilation (LAMA + LABA): Indicated for patients with persistent dyspnoea or recurrent exacerbations on monotherapy. Fixed-dose single-inhaler LAMA/LABA combinations achieve superior bronchodilation and lung deflation.

COPD inhaled corticosteroids: Consider exacerbation history, blood eosinophils and coexisting asthma. Benefits and pneumonia risks differ between patients; neither a single eosinophil value nor the COPD label alone supplies a universal indication or prohibition.

Primary references (checked 7 October 2026): Australian Asthma Handbook .